<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Limited has submitted a mandatory disclosure to BSE confirming its status as a 'Not a Large Corporate' under the SEBI framework governing fund raising through debt securities by large entities. The disclosure, dated April 23, 2025, was filed by Director Prakash Shah pursuant to SEBI Circulars dated November 26, 2018 and October 19, 2023. As a non-large corporate, the company is not obligated to raise a minimum portion of its funding through the debt securities route. The company is registered in Mumbai and operates with CIN L24200MH1987PLC043427.
This is a routine annual regulatory compliance filing with no material impact on shareholders or stock price. It simply confirms the company falls below the threshold to be classified as a large corporate, meaning no debt issuance obligations apply.